AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Employees - 50000,
CEO - Mr. Robert A. Michael,
Sector - Healthcare,
Country - US,
Market Cap - 317.62B
Altman ZScore(max is 10): 1.93, Piotroski Score(max is 10): 5, Working Capital: $-15277000000, Total Assets: $143422000000, Retained Earnings: $-4964000000, EBIT: 15884000000, Total Liabilities: $137351000000, Revenue: $55533000000
- Current Price $175.58 - Analyst Target Price $204.08Ticker | ABBV |
Index | S&P 500 |
Curent Price | 175.58 |
Change | 2.37% |
Market Cap | 317.62B |
Average Volume | 6.23M |
Income | 5.08B |
Sales | 55.53B |
Book Value/Share | 3.41 |
Cash/Share | 4.03 |
Dividend Est | 6.17 (3.51%) |
Dividend TTM | 6.20 (3.53%) |
Dividend Ex-Date | Jan 15, 2025 |
Employees | 50000 |
Moving Avg 20days | -0.62% |
Moving Avg 50days | -3.93% |
Moving Avg 200days | -1.82% |
Shares Outstanding | 1.77B |
Earnings Date | Oct 30 BMO |
Inst. Ownership | 72.95% |
Price/Earnings | 61.23 |
Forwad P/E | 14.39 |
PE Growth | 7.29 |
Price/Sales | 5.72 |
Price/Book | 51.44 |
Price/Cash | 43.60 |
Price/FCF | 20.38 |
Quick Ratio | 0.54 |
Current Ratio | 0.65 |
Debt/Equity | 11.78 |
Return on Assets | 3.63% |
Return on Equity | 56.06% |
Return on Investment | 7.87% |
Gross Margin | 69.87% |
Ops Margin | 30.61% |
Profit Margin | 9.15% |
RSI | 46.96 |
BETA(β) | 0.57 |
From 52week Low | 16.06% |
From 52week High | -15.31% |
EPS | 2.87 |
EPS next Year | 12.20 |
EPS next Qtr | 2.98 |
EPS this Year | -1.53% |
EPS next 5 Year | 8.40% |
EPS past 5 Year | -5.77% |
Sales past 5 Year | 11.76% |
EPS Y/Y | -21.61% |
Sales Y/Y | 0.72% |
EPS Q/Q | -12.27% |
Sales Q/Q | 3.83% |
Sales Surprise | 1.24% |
EPS Surprise | 2.74% |
ATR(14) | 4.01 |
Perf Week | 1.27% |
Perf Month | 4.66% |
Perf Quarter | -9.42% |
Perf Year | 15.75% |
Perf YTD | 13.30% |
Target Price | 204.08 |
AryaFin Engine© - An AI FinTech Venture - 2024 Disclaimer